0
Signin
countryflagCA

888-969-2592

RY 144.17 0.4529% TD 77.39 0.0517% SHOP 78.87 -1.3878% CNR 171.64 0.5625% ENB 50.09 -0.4769% CP 110.62 0.6277% BMO 128.85 -0.548% TRI 233.58 1.1563% CNQ 103.29 -0.174% BN 60.87 -0.2295% ATD 75.6 -1.447% CSU 3697.0 1.1582% BNS 65.76 -0.3485% CM 66.6 -0.5525% SU 54.21 1.1569% TRP 53.15 0.3398% NGT 58.54 -0.3405% WCN 226.5 0.4123% MFC 35.905 0.9986% BCE 46.75 -0.5954%

Profound Medical Corp

Healthcare CA PRN

11.59CAD
0.07(0.61%)

Last update at 2024-05-16T19:44:00Z

Day Range

11.5911.98
LowHigh

52 Week Range

9.5520.44
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -28.38200M -30.59400M -21.57700M -15.30953M -15.07471M
Minority interest - - - - -
Net income -28.66900M -30.69900M -21.62200M -15.45795M -15.24415M
Selling general administrative 9.46M 10.31M 7.57M 5.88M 4.89M
Selling and marketing expenses 8.47M 7.65M 4.86M 2.14M 3.00M
Gross profit 3.02M 2.95M 3.47M 2.42M 0.60M
Reconciled depreciation 1.60M 1.88M 1.54M 1.54M 1.23M
Ebit -29.60200M -30.29100M -18.86300M -15.13324M -14.31933M
Ebitda -25.47400M -28.41200M -16.63300M -13.22312M -13.08996M
Depreciation and amortization 4.13M 1.88M 2.23M 1.91M 1.23M
Non operating income net other - - - - -
Operating income -29.60200M -30.29100M -18.86300M -15.13324M -14.82698M
Other operating expenses 36.28M 37.16M 26.17M 19.36M 16.74M
Interest expense 0.17M 0.30M 0.54M 0.54M 0.76M
Tax provision 0.29M 0.10M 0.04M 0.19M 0.23M
Interest income 3.45M 0.14M 2.62M 1.20M 0.73M
Net interest income 0.92M -0.31000M 0.15M -0.88862M -0.54505M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.29M 0.10M 0.04M 0.15M 0.17M
Total revenue 6.68M 6.87M 7.30M 4.23M 1.91M
Total operating expenses 32.62M 33.24M 22.34M 17.56M 15.43M
Cost of revenue 3.66M 3.92M 3.83M 1.81M 1.31M
Total other income expense net 1.22M -0.30300M -2.71400M -0.17629M -0.24773M
Discontinued operations - - - - -
Net income from continuing ops -28.66900M -30.69900M -21.62200M -20.19225M -20.76299M
Net income applicable to common shares -28.66900M -30.69900M -21.62200M -15.22200M -20.76299M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 64.42M 86.78M 104.60M 29.89M 34.18M
Intangible assets 0.68M 1.44M 1.90M 2.40M 2.95M
Earning assets - - - - -
Other current assets 1.22M 1.15M 1.07M 1.02M 0.32M
Total liab 12.42M 6.16M 7.25M 15.60M 14.63M
Total stockholder equity 52.00M 80.62M 97.35M 14.29M 19.55M
Deferred long term liab - - - - -
Other current liab 0.92M 0.25M 0.76M 0.53M 1.48M
Common stock 205.82M 219.58M 211.53M 99.72M 88.79M
Capital stock 205.82M 219.58M 211.53M 99.72M 88.79M
Retained earnings -189.36200M -160.69300M -129.99400M -100.33568M -81.52072M
Other liab 0.76M 0.88M 1.08M 0.65M 1.43M
Good will 0.00000M 2.69M 2.68M 2.61M 2.50M
Other assets - 3.62M - - -
Cash 46.52M 67.15M 83.91M 14.72M 22.53M
Cash and equivalents - - - - -
Total current liabilities 4.18M 4.16M 4.81M 8.18M 5.79M
Current deferred revenue 0.47M 0.48M 0.36M 0.50M 0.23M
Net debt -38.28700M -65.77500M -82.23700M -3.80722M -13.75296M
Short term debt 0.76M 0.25M 0.31M 4.14M 0.98M
Short long term debt 0.52M - - 5.14M 1.34M
Short long term debt total 8.23M 1.38M 1.68M 10.91M 8.78M
Other stockholder equity 18.70M 16.99M 11.25M 14.99M 12.30M
Property plant equipment 1.72M 1.90M 2.28M 2.22M 1.21M
Total current assets 62.02M 77.12M 97.74M 22.68M 27.84M
Long term investments - - - - -
Net tangible assets 51.32M 76.49M 92.77M 9.34M 19.20M
Short term investments - - - - -
Net receivables 6.34M 1.41M 7.43M 3.29M 1.79M
Long term debt 6.65M - 0.00000M 6.72M 10.62M
Inventory 7.94M 7.41M 5.33M 3.65M 2.67M
Accounts payable 2.03M 3.18M 3.38M 3.01M 2.87M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 16.84M 4.75M 4.57M -0.08971M -0.02107M
Additional paid in capital - - - - -
Common stock total equity - - 211.53M 130.27M 120.93M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 3.62M - 0.00000M 0.00000M
Deferred long term asset charges - - - - -
Non current assets total 2.40M 9.65M 6.86M 7.21M 6.34M
Capital lease obligations 1.06M 1.38M 1.68M 2.38M -
Long term debt total 7.47M 1.13M 1.36M 8.85M 10.62M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.00000M -0.59300M -0.35000M -0.25000M 0.00000M
Change to liabilities -0.56600M -0.35600M 0.28M 0.10M -0.95705M
Total cashflows from investing activities 0.00000M -0.59300M -0.35000M -0.18900M -0.18900M
Net borrowings 6.92M -0.38600M -9.60600M -1.25000M 12.33M
Total cash from financing activities 7.03M 5.95M 87.43M 6.75M 27.81M
Change to operating activities -2.08600M -0.01300M 1.25M -1.73600M 0.46M
Net income -28.66900M -30.69900M -21.62200M -15.45795M -15.24415M
Change in cash -20.63500M -16.76100M 69.11M -8.77689M 14.38M
Begin period cash flow 67.15M 83.91M 14.80M 23.49M 8.15M
End period cash flow 46.52M 67.15M 83.91M 14.72M 22.53M
Total cash from operating activities -25.80000M -22.36000M -20.57400M -15.33408M -13.43189M
Issuance of capital stock - 0.00000M 85.52M 8.80M 25.33M
Depreciation 1.60M 1.88M 1.54M 1.54M 1.23M
Other cashflows from investing activities - - - - 0.00000M
Dividends paid - - - - -
Change to inventory -1.86400M -2.49100M -2.14100M -0.86723M -1.61558M
Change to account receivables -1.42400M 2.00M -4.02800M -1.05034M 1.15M
Sale purchase of stock 0.26M 6.43M 103.68M 11.51M 34.61M
Other cashflows from financing activities 7.39M 6.33M 11.52M -0.79197M 6.78M
Change to netincome 6.89M 7.34M 4.14M 2.40M 2.15M
Capital expenditures 0.00000M 0.59M 0.35M 0.19M 0.03M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -5.62900M -0.87700M -4.63500M -3.73538M -0.99083M
Stock based compensation 4.24M 7.21M 3.02M 1.28M 0.80M
Other non cash items 2.66M 0.13M 1.13M 1.03M 0.78M
Free cash flow -25.80000M -22.95300M -20.92400M -15.52546M -13.43189M

Fundamentals

  • Previous Close 11.52
  • Market Cap263.15M
  • Volume1275
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-25.98200M
  • Revenue TTM6.45M
  • Revenue Per Share TTM0.31
  • Gross Profit TTM 3.02M
  • Diluted EPS TTM-1.87

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PRN
Profound Medical Corp		 0.07 0.61% 11.59 - - 40.82 5.05 35.48 -9.6771
QIPT
Quipt Home Medical Corp.		 -0.68 12.59% 4.72 - - - -
HTL
Hamilton Thorne Ltd.		 0.02 1.45% 1.40 - - - -
TMD
Titan Medical Inc		 -0.005 8.33% 0.06 - - 0.59 2.03 0.54 -0.3059

Reports Covered

Stock Research & News

View All

Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, palliative pain treatment of bone metastases, and osteoid osteoma. Profound Medical Corp. is headquartered in Mississauga, Canada.

Profound Medical Corp

2400 Skymark Avenue, Mississauga, ON, Canada, L4W 5K5

Key Executives

Name Title Year Born
Dr. Arun Swarup Menawat MBA, Ph.D. Chairman & CEO 1955
Mr. Rashed Dewan Chief Financial Officer 1968
Dr. Mathieu Burtnyk Sr. VP of Product Leader TULSA-PRO 1982
Mr. Stephen Kilmer Investor Relations NA
Mr. Hartmut Warnken Chief Commercial Officer of OUS NA
Mr. Jacques F. Cornet Sr. VP & Product Leader Sonalleve 1956
Mr. Michael Mydra VP & Head of Global Market Access NA
Mr. Abbey Goodman Chief Commercial Officer of US NA
Mr. Matthew Sobczyk C.A., CPA Assistant Corp. Controller NA
Mr. Levant Tinaz Software Developer NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).